CLOSE
Search

scientists collaborate - search results

If you're not happy with the results, please do another search

by -
0 74
Assemblyman Steve Englebright (D-Setauket) during a press conference at Port Jefferson Harbor. The LIPA power plant can be seen in the distance. File photo by David Luces

As the federal government under the current presidential administration has scaled back environmental measures — and at points denied the science behind climate change —members in the New York State Legislature are trying to go about it without the leadership of Uncle Sam.

That is, if it can pass before the end of legislative session.

“New York has to help lead the way, because we’re not getting any leadership at the federal level,” said Assemblyman Steve Englebright (D-Setauket). 

“You can just look at the weather reports for the nation — last year California burned, this year Texas is drowning. The amount of rain we’re getting is a result of an overheated ocean relaying more rain to the atmosphere. And on it goes.”

— Steve Englebright

Englebright, the chair of the environmental conservation committee, is sponsoring the Climate and Community Protection Act, which would establish a New York State Climate Action Council. It would contain 25 members made up of state agencies, scientists and those in the environmental justice, labor and other regulated industries. The council would be able to make recommendations to the state Department of Environmental Conservation to limit greenhouse gases. It would also be asked to report on barriers to and opportunities for community ownership of services and commodities in certain communities, particularly for renewable energy.

“An advisory committee that will have meaningful powers to make recommendations as we go forward — the stakes are so high on this issue,” Englebright said.

In addition, the bill would require the DEC to establish greenhouse gas reporting requirements and limits on emissions.

The bill was passed in the environmental committee and was referred to the ways and means committee in February.

The idea of an advisory committee is not new. A similar advisory panel was suggested in the New York State 2019-20 budget, but it was removed in the final version because some legislators disagreed with the number of people on the board and who would sit on it.

“Instead of 25, [Cuomo] had nine appointees; six of them are his cabinet members,” Englebright said.

In January during the process for crafting the budget, Gov. Andrew Cuomo (D) incited a “Green New Deal,” which would have been “comprised of the heads of relevant state agencies and other workforce, environmental justice and clean energy experts,” according to a January press release. The governor has set goals to reduce greenhouse gas emissions in New York State by 80 percent below the levels emitted in 1990 by the year 2050.

A spokesperson from the governors office said the governor is continuing to collaborate with the legislature on climate policy proposals.

Cuomo appeared on city radio WNYC’s show hosted by Brian Lehrer June 3. When the new climate change legislation was brought up, he said he was looking to attack the issue while not pretending change will happen all at once.

“I believe this is the most pressing issue of our time, but I don’t want to play politics with it and I don’t want to tell people we can move to a carbon free economy in a period of time that I know that we can’t.”

The end of this legislative session is June 19, and Englebright said he is crossing his fingers the bill can pass both assembly and senate before time runs out. 

He said the bill is especially important with the current administration in Washington. The New York Times reported June 3 that 84 environmental rules and regulations are being phased out by Trump and his appointees.

“We are seeing the effects of increased carbon dioxide and methane in the atmosphere on a daily basis,” he said. “You can just look at the weather reports for the nation — last year California burned, this year Texas is drowning. The amount of rain we’re getting is a result of an overheated ocean relaying more rain to the atmosphere. And on it goes.”

by -
0 1782
Gordon Taylor with technician, Tatiana Zaliznyak. A Raman microspectrometer is pictured in the background. Photo by J. Griffin

By Daniel Dunaief

Something is happening in the Twilight Zone of the ocean, but it’s unclear exactly who is involved and how fast the process is occurring. 

Plants and animals are eating, living, defecating and dying above the so-called Twilight Zone and their bodies and waste are falling toward the bottom of the ocean. But most of that matter isn’t making it all the way to the ocean floor.

That’s where Gordon Taylor, a professor and director of the NAno-RAMAN Molecular Imaging Laboratory at the School of Marine & Atmospheric Sciences at Stony Brook University, comes in. 

Taylor and Professor Alexander Bochdansky of Old Dominion University recently received a $434,000 three-year grant to study the way microorganisms eat, process and convert organic carbon — i.e., carbon that’s a part of living organisms like plants, sea birds and whales — into inorganic carbon, which includes carbon dioxide, carbonate, bicarbonate and carbonic acid.

“The inorganic carbon moves back and forth among these four chemical species,” Taylor explained in an email. Understanding the rate at which carbonic acid builds up can and will help lead to a greater awareness of ways the ocean, which used to have a pH around 8.2 — which is slightly basic, as opposed to levels below the neutral 7— is becoming more acidic.

Above, incubators that Alexander Bochdansky has used in Bermuda. The ones Taylor and Bochdansky will analyze will be smaller than these, which won’t require such a large A-frame to deploy. Images courtesy of A. Bochdansky

They will start by deploying the traps at a single depth, about 985 feet, along the ocean off the coast of Virginia. “We are going to look at who the players are,” Bochdansky said. “There might be only a few key players that degrade this organic carbon. With [Taylor’s] great methods, we can measure the uptake rate in single microbes. This is really exciting.”

The Twilight Zone received its name because it is 650 to 3,300 feet below the surface of the water. Some faint light reaches the top of that zone, but most of that region, which includes creatures that use bioluminescence to attract or find prey, is pitch black.

“The directory of which inventories and fluxes decrease [is] still poorly understood,” Taylor said. “Animals eating the material is one mechanism and we don’t know how important that is compared to microbial decomposition or remineralization,” adding that the goal of this project is to “better define the role of microorganisms in returning carbon to the inorganic pool.”

Taylor is exploring this area with new tools that will allow a greater depth of understanding than previously possible. His group has developed new experimental approaches to apply Raman microspectrometry to this problem. The organisms they examine will include bacteria, fungi and protozoans.

Their experiment will explore which organisms are recycling organic carbon, how fast they are doing it and what factors control their activities. Through this approach, Taylor will be able to see these processes down to the level of a single cell as the instrument can identify organisms that have consumed the heavy isotope tracer.

The Raman microspectrometer uses an optical microscope with a laser and a Raman spectrometer. This tool will measure samples that are micrometers thick, which is smaller than the width of a human hair. The microspectrometer can obtain data from a 0.3-micrometer spot in a cell and he has even produced spectra from single viruses.

The scientists will place phytoplankton common to the region in incubators that Bochdansky developed. They will use a heavy carbon isotope, called carbon 13, that is easy to find through these experiments and see how rapidly microorganisms that colonize are incorporating the isotopically labeled carbon.

Taylor and Bochdansky received funding for the project through the Biological Oceanography Program at the National Science Foundation in the Directorate of Geosciences. Twice a year, the division makes open calls for proposals on any topic of interest to researchers. The scientists submit 15 pages of text that the NSF sends to peer reviewers. A panel meets to evaluate the reviews and ratings and decides which projects to fund.

Bochdansky and Taylor have been “acquainted for a long time and have shared similar interests,” Taylor said.

The carbon experiments in the Twilight Zone account for about a quarter of the work Taylor is doing in his lab. The other research also employs Raman microspectrometry. The United States only has one or two other facilities that do environmental research comparable to the one in Taylor’s lab at Stony Brook. Europe also has three such tools, which can look into single cells using lasers.

One of the other projects Taylor hopes to get funded involves studying the distribution of microplastics in the ocean. “The instrument I have is one of the best tools to look at microscopic plastic particles,” because it identifies the plastic polymer and its source, said Taylor, who is awaiting word on funding from the National Oceanic and Atmospheric Administration.

The other work involves exploring viruses that attack plankton.

“We are exploring Raman methods for early detection of viruses that attack plankton,” Taylor explained. Every organism in the ocean has at least one virus that has evolved to attack it.

As for his work on the Twilight Zone, Taylor said the area acts as a filter of sorts because less than 20 percent of the organic material entering at the top exits at the bottom.

Bochdansky added that these microbes are critical to processes that affect oceans and the planet.

“That’s something people often overlook,” Bochdansky said. “We can’t understand the ocean if we don’t understand it at the level or the scale that’s relevant to microbes.”

Bochdansky is thrilled to work with Taylor, who he’s known for years but will collaborate with for the first time on this project.

“In my lab, we have measured the turnover and release of carbon dioxide,” Bochdansky said. In Taylor’s lab, he measures “the actual feeding of microbial cells.”

by -
0 2556
From left, Megan Crow, Associate Professor Jesse Gillis and postdoctoral researcher Sara Ballouz Photo by Gina Motisi/CSHL

By Daniel Dunaief

Diversity has become a buzz word in the workplace, as companies look to bring different perspectives that might represent customers, constituents or business partners. The same holds true for the human brain, which contains a wide assortment of interneurons that have numerous shapes and functions.

Interneurons act like a negative signal or a brake, slowing or stopping the transmission. Like a negative sign in math, though, some interneurons put the brakes on other neurons, performing a double negative role of disinhibiting. These cells of the nervous system, which are in places including the brain, spinal chord and retina, allow for the orderly and coordinated flow of signals.

One of the challenges in the study of these important cells is that scientists can’t agree on the number of types of interneurons.

“In classifying interneurons, everyone argues about them,” said Megan Crow, a postdoctoral researcher in Jesse Gillis’ lab at Cold Spring Harbor Laboratory. “People come to this question with many different techniques, whether they are looking at the shape or the connectivity or the electrophysiological properties.”

Megan Crow. Photo by Constance Brukin

Crow recently received a two-year grant from the National Institutes of Health to try to measure and explain the diversity of interneurons that, down the road, could have implications for neurological diseases or disorders in which an excitatory stimulus lasts too long.

“Understanding interneuron diversity is one of the holy grails of neuroscience,” explained Gillis in an email. “It is central to the broader mission of understanding the neural circuits which underlie all behavior.”

Crow plans to use molecular classifications to understand these subtypes of neurons. Her “specific vision” involves exploiting “expected relationships between genes and across data modalities in a biologically thoughtful way,” said Gillis.

Crow’s earlier research suggests there are 11 subtypes in the mouse brain, but the exact number is a “work in progress,” she said.

Her work studying the interneurons of the neocortex has been “some of the most influential work in our field in the last two to three years,” said Shreejoy Tripathy, an assistant professor in the Department of Psychiatry at the University of Toronto. Tripathy hasn’t collaborated with Crow but has been aware of her work for several years.

The interactivity of a neuron is akin to personalities people demonstrate when they are in a social setting. The goal of a neuronal circuit is to take an input and turn it into an output. Interneurons are at the center of this circuit, and their “personalities” affect the way they influence information flow, Crow suggested.

“If you think of a neuron as a person, there are main personality characteristics,” she explained. Some neurons are the equivalent of extraverted, which suggests that they have a lot of adhesion proteins that will make connections with other cells.

“The way neurons speak to one another is important in determining” their classes or types, she said.

A major advance that enabled this analysis springs from new technology, including single-cell RNA sequencing, which allows scientists to make thousands of measurements from thousands of cells, all at the same time.

“What I specialize in and what gives us a big leg up is that we can compare all of the outputs from all of the labs,” Crow said. She is no longer conducting her own research to produce data and, instead, is putting together the enormous volume of information that comes out of labs around the world.

Megan Crow. Photo by Daniel Katt

Using data from other scientists does introduce an element of variability, but Crow believes she is more of a “lumper than a splitter,” although she would like to try to understand variation where it is statistically possible.

She believes in using data for which she has rigorous quality control, adding, “If we know some research has been validated externally more rigorously than others, we might tend to trust those classifications with more confidence.”

Additionally she plans to collaborate with Josh Huang, the Charles Robertson professor of neuroscience at Cold Spring Harbor Laboratory, who she described as an interneuron expert and suggested she would use his expertise as a “sniff test” on certain experiments.

At this point, Crow is in the process of collecting baseline data. Eventually, she recognizes that some interneurons might change in their role from one group to another, depending on the stimuli.,

Crow hasn’t always pursued a computational approach to research. 

In her graduate work at King’s College London, she produced data and analyzed her own experiments, studying the sensory experience of pain.

One of the challenges scientists are addressing is how pain becomes chronic, like an injury that never heals. The opioid crisis is a problem for numerous reasons, including that people are in chronic pain. Crow was interested in understanding the neurons involved in pain, and to figure out a way to treat it. “The sensory neurons in pain sparked my general interest in how neurons work and what makes them into what they are,” she said.

Crow indicated that two things brought her to the pain field. For starters, she had a fantastic undergraduate mentor at McGill University, Professor of Psychology Jeff Mogil, who “brought the field to life for me by explaining its socio-economic importance, its evolutionary ancient origins, and showed me how mouse behavioral genetic approaches could make inroads into a largely intractable problem.”

Crow also said she had a feeling that there might be room to make an impact on the field by focusing on molecular genetic techniques rather than the more traditional electrophysiological and pharmacological approaches.

As for computational biology, she said she focuses on interpreting data, rather than in other areas of the field, which include building models and simulations or developing algorithms and software.

In the bigger picture, Crow said she’s still very interested in disease and would like to understand the role that interneurons and other cells play. “If we can get the tools to be able to target” some of the cells involved in diseases, “we might find away to treat those conditions.”

The kind of research she is conducting could start to provide an understanding of how cells interact and what can go wrong in their neurodevelopment.

Gillis praises his postdoctoral researcher for the impact of her research.

“Just about any time [Crow] has presented her work — and she has done it a lot — she has ended up convincing members of the audience so strongly that they either want to collaborate, adapt her ideas, or recruit her,” Gillis wrote in an email. 

Crow grew up in Toronto, Canada. She said she loved school, including science and math, but she also enjoyed reading and performing in school plays. She directed a play and was in “The Merchant of Venice.” In high school, she also used to teach skiing.

A resident of Park Slope in Brooklyn, Crow commutes about an hour each way on the train, during which she can do some work and catch up on her reading.

She appreciates the opportunity to work with other researchers at Cold Spring Harbor, which has been “an incredible learning experience.”

by -
0 163
From left, Supervisor Ed Romaine, Councilman Dan Panico, honoree Cathy Cutler and Town of Brookhaven Receiver of Taxes Louis Marcoccia at the March 21 event. Photo from BNL

Cathy Cutler, director of the Medical Isotope Research & Production program at the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory, was honored for her scientific accomplishments at Town of Brookhaven’s 33rd annual Women’s Recognition Night, held on March 21 at Town Hall in Farmingville. The Shirley resident was among 13 women honored for their contributions to a variety of fields at a public ceremony that celebrated the significant achievements of local women during Women’s History Month.

At BNL, Cutler and her team collaborate on research with radiopharmaceuticals for cancer therapy, and they make radioisotopes required for this research as well. These radioisotopes would otherwise not be available but are, thanks to the high-energy Brookhaven Linac Isotope Producer (BLIP) that is part of the extensive particle accelerator infrastructure for the Relativistic Heavy Ion Collider — a U.S. Department of Energy Office of Science User Facility for fundamental nuclear physics research located at Brookhaven.

Radiopharmaceuticals are vital for “noninvasive,” personalized cancer treatments that provide patients with high-impact doses to combat tumors without damaging nearby healthy cells. With more than 20 years’ experience developing and evaluating radiopharmaceuticals, Cutler is helping lead their development for “theranostics” that combine medical therapies with diagnostic medical tests.

“I am honored to receive this award from the Town of Brookhaven,” said Cutler, who acknowledged the contributions of her colleagues in the success of her research and the isotope program at BNL. “Brookhaven Lab is one of just a few facilities in the DOE complex that can produce certain critical medical isotopes. We are hopeful that this research will lead to improved treatment options for cancer patients.”

“The Town of Brookhaven is pleased to recognize Cathy Cutler for her achievements as an outstanding scientist, leader, and role model for those aspiring to careers in science, technology, and engineering,” said Town of Brookhaven Supervisor Ed Romaine (R).

Cutler joined BNL in 2015 after earning a doctorate in inorganic chemistry from the University of Cincinnati and spending nearly 17 years at the University of Missouri Research Reactor Center. She serves as a mentor to young scientists, has received numerous awards and holds several patents.

In addition to her role at the lab, Cutler has served as chair of the Society of Nuclear Medicine and Molecular Imaging’s committee on radiopharmaceuticals. She is a board member for the society’s Therapy Center of Excellence and Center for Molecular Imaging Innovation and Translation and an executive board member for the Society of Radiopharmaceutical Sciences.

For more information, please visit www.science.energy.gov.

by -
0 2277
Lori Chan, standing, in the lab with doctoral student Jiabei He. Photo from SBU

By Daniel Dunaief

It’s like a factory that makes bombs. Catching and removing the bombs is helpful, but it doesn’t end the battle because, even after many or almost all of the bombs are rounded up, the factory can continue to produce damaging products.

That’s the way triple-negative breast cancer operates. Chemotherapy can reduce active cancer cells, but it doesn’t stop the cancer stem cell from going back into the cancer-producing business, bringing the dreaded disease back to someone who was in remission.

Scientists who stop these cancer stem cells would be doing the equivalent of shutting down the factory, reducing the possible return of a virulent type of cancer.

Lori Chan, an assistant professor in the Department of Pharmacological Sciences in the Renaissance School of Medicine at Stony Brook University, recently published research in Cell Death & Disease that demonstrated the role of a specific gene in the cancer stem cell pathway. Called USP2, this gene is overexpressed in 30 percent of all triple-negative breast cancers.

Inhibiting this gene reduced the production of the tumor in a mouse model of the disease.

Chan’s results “suggest a very important role [of this gene] in cancer stem cells,” Yusuf Hannun, the director of the Stony Brook University Cancer Center, explained in an email.

Lori Chan with her dog KoKo. Photo by Joshua Lee

Chan used a genetic and a pharmacological approach to inhibit USP2 and found that both ways shrink the cancer stem cell population. She used RNA interference to silence the gene and the protein expression, and she also used a USP2-specific small molecular inhibitor to block the activity of the USP2 protein.

With the knowledge that the cancer stem cell factory population needs this USP2 gene, Chan inhibited the gene while providing doxurubicin, which is a chemotherapy treatment. The combination of treatments suppressed the tumor growth by 50 percent.

She suggested that the USP2 gene can serve as a biomarker for the lymph metastasis of triple-negative breast cancer. She doesn’t know if it could be used as a biomarker in predicting a response to chemotherapy. Patients with a high expression of this gene may not respond as well to standard treatment.

“If a doctor knows that a patient probably wouldn’t respond well to chemotherapy, the doctor may want to reconsider whether you want to put your patient in a cycle for chemotherapy, which always causes side effects,” Chan said.

While this finding is an encouraging sign and may allow doctors to use this gene to determine the best treatment, the potential clinical benefit of this discovery could still be a long way off, as any potential clinical approach would require careful testing to understand the consequences of a new therapy.

“This is the beginning of a long process to get to clinical trials and clinical use,” Hannun wrote. Indeed, researchers would need to understand whether any treatment caused side effects to the heart, liver and other organs, Chan added. 

In the future, doctors at a clinical cancer center might perform a genomic diagnostic, to know exactly what type of cancer an individual has. Reducing the cancer stem cell population can be critically important in leading to a favorable clinical outcome.

A few hundred cancer cells can give rise to millions of cancer cells. “I want to let chemotherapy do its job in killing cancer cells and let [cancer stem cell] targeted agents, such as USP2 inhibitors, prevent the tumor recurrence,” Chan said. 

She urges members of the community to screen for cancer routinely. A patient diagnosed in stage 1 has a five-year survival rate of well over 90 percent, while that rate plummets to 15 to 20 percent for patients diagnosed with stage 4 cancer.

The next step in Chan’s research is to look for ways to refine the inhibitor to make it more of a drug and less of a compound. She is also interested in exploring whether USP2 can be involved in other cancers, such as lung and prostate, and would be happy to collaborate with other scientists who focus on these types of cancers.

For Chan, the moment of recognition of the value of studying this gene in this form of breast cancer came when she compared the currently used drug with and without the inhibitor compound. With the inhibitor, the drug becomes much more effective.

A resident of Stony Brook, Chan lives with her husband, Joshua Lee, who is working in the same lab. The couple, who have a 1½-year-old rescue dog from Korea named KoKo, met when they were in graduate school.

Concerned about snow, which she hadn’t experienced when she was growing up in Taiwan, Chan started her tenure at Stony Brook five years ago on April 1, on the same day a snowstorm blanketed the area. “It was a very challenging first day,” she recalled. She now appreciates snow and enjoys the seasonal variety on Long Island.

Chan decided to pursue a career in cancer research after she volunteered at a children’s cancer hospital in Taiwan. She saw how desperate the parents and the siblings of the patient were. In her role as a volunteer, she played with the patients and with their siblings, some of whom she felt didn’t receive as much attention from parents who were worried about their sick siblings.

“This kind of disease doesn’t just take away one person’s life,” Chan said. “It destroys the whole family.” When she went to graduate school, she wanted to know everything she could about how cancer works.

Some day Chan hopes she can be a part of a process that helps doctors find an array of inhibitors that are effective in treating patients whose cancers involve the overexpression of different genes. “It would be a privilege to participate in this process,” she said.

by -
0 1194
Sean Clouston

By Daniel Dunaief

Every year, the country pauses on 9/11, remembering the victims of the terrorist attacks and reflecting on the safety and security of the country. At the same time, a Stony Brook University study continues not only to remember the first responders but also to understand the physical and mental consequences of the work police, firefighters and other first responders performed in the immediate aftermath of the attacks.

Benjamin Luft

Recently, Sean Clouston, an associate professor in the Department of Family, Population & Preventive Medicine at SBU Renaissance School of Medicine, and Ben Luft, the director of the SBU WTC Health and Wellness Program since 2003, published research in which they demonstrated a link between a protein commonly connected with Alzheimer’s disease to post-traumatic stress disorder, or PTSD, in first responders.

In a small preliminary study, the researchers found a difference in the level of the protein between first responders who are battling chronic PTSD and those who aren’t battling the condition. The Stony Brook scientists published their work in the journal Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring.

The researchers cautioned that the presence of the markers doesn’t necessarily indicate anything about present or future changes in cognitive function.“We don’t know the specificity of the markers,” Luft explained in an email.

Amyloid is generally considered the earliest marker of Alzheimer’s disease, which includes cognitive decline. Some people, however, have significant amounts of amyloid and don’t develop problems with their thinking. Neurodegenerative diseases without amyloid rarely have severe symptoms, which don’t appear to worsen with time.

“This paper doesn’t look at cognitive symptoms,” Clouston said. “We do have papers looking at cognitive impairment and other memory-based differences. It wasn’t a part of this paper.”

The newest research is part of an ongoing program in which the university follows 11,000 responders who came to the World Trade Center. The study for this paper involved a smaller subset of this population. This type of research can and does have application to other studies of people who have traumatic experiences, the scientists suggest.

Most traumatic experiences are unique to each person, as people who suffer physical and emotional trauma in combat often confront the aftereffects of head injuries. Among the first responder population who survived the attacks on 9/11, most of them “faired pretty well physically,” Clouston said. 

“We didn’t have a lot of head injuries. Understanding PTSD in this crowd is really useful for the literature as a whole because it allows us to focus on the long-term psychiatric fallout of an event without worrying about exposures that are different.”

The scientists had at least some idea of the timing and duration of exposures. This research suggests that it might be helpful to think about the kinds of problems that cognitive impairment can cause, which might involve managing other health-related problems.

Luft added that the population they are studying shows the benefit of immediate care. “One thing for sure is that the care of the first responders has to occur very quickly,” he said. “Now that we know the history, the greatest chance you have in mitigating the effect of this type of trauma is to deal with the problem from the get-go.” 

Sean Clouston with his daughter Quinn at Benner’s Farm in Setaukt. with his daughter Quinn. Photo by Rachel Kidman

First responders have benefited from psychotherapy as well as from various pharmacological treatments. Luft suggested that they might even benefit from having therapists available in the field, where they can receive near instantaneous psychological support.

In addition to the psychological trauma, first responders have had physical effects from their work in the aftermath of the attacks, such as respiratory and gastrointestinal problems, as well as autoimmunity issues.

People have these problems because “of the pro-inflammatory effect of PTSD itself,” said Luft. The researchers believe trauma can affect the immune system and the brain.

According to Clouston, the next step with this work is to replicate it with a larger scale. The experiment was “fairly expensive and untried in this population and novel in general, so we started small,” he explained in an email. The scientists would like to “get a larger range of responders and to examine issues surrounding symptomatology and other possible explanations.”

Clouston has been at Stony Brook for six years. Prior to his arrival on Long Island, he worked on a collaborative project that was shared between University College London and the University of Victoria. 

An expert in aging, he felt like his arrival came at just the right time for the WTC study, as many of the first responders were turning 50. After giving talks about the cognitive and physical effects of aging, he met Luft and the two decided to collaborate within six months of his arrival.

Clouston is focused on whether PTSD caused by the terrorist attacks themselves have caused early brain aging. A self-proclaimed genetics neophyte, he appreciates the opportunity to work with other researchers who have considerably more experience in searching for molecular signatures of trauma.

Clouston said his family has suffered through the trauma of cognitive decline during the aging process. His family’s struggles “definitely bring [the research] home,” reminding him of the “terror that many family members feel when they start noticing problems in their siblings, parents, spouses, etc.”

As for his work on the recent study, he said he is excited about the next steps. “Little is known about the subtypes of amyloid,” he suggested and there’s a “lot more to explore about the role [of this specific type] in the population. I do think it could be really informative about the types of symptoms.”

by -
0 2461
Alexander Orlov, right, with former students, Peichuan Shen and Shen Zhao. File photo

By Daniel Dunaief

Alexander Orlov knows first-hand about the benefits and dangers of technology. A native of the Ukraine, Orlov and his family lived close enough to Chernobyl that the 1986 nuclear power plant disaster forced the family to bring a Geiger counter to the supermarket. In his career, the associate professor in the Material Science and Chemical Engineering Department at Stony Brook University has dedicated himself to unlocking energy from alternatives to fossil fuels, while he also seeks to understand the environmental consequences of the release of nanoparticles.

Orlov, who is a member of a US-EU working group on Risk Assessment of Nanomaterials and has served as science adviser to several congressmen, the EU Commission and governments in Europe and Asia, recently spoke with Times Beacon Record News Media about this expanding scientific field.

Alexander Orlov File photo

TBR: Is a big part of what you do understanding the way small particles can help or hurt people and the environment?

Orlov: Yes, we have two lines of research. The first is to make efficient nanoparticles, which can help create sustainable energy by creating energy from water or by taking carbon dioxide, which is greenhouse gas, and converting it into fuel. On the other side, we have a project, which is looking at the dangers of nanoparticles in the environment, because there are more and more products, thousands, which contain nanoparticles. We are trying to understand the mechanism of release of those particles.

TBR: How do you monitor the release of nanomaterials?

Orlov: We use labels, and we track them. If they are released from consumer products, it’s not necessarily that they are immediately dangerous. They can be. We are trying to quantify how much is released.

TBR: How do you determine toxicity?

Orlov: In the scientific arena, there is a qualitative discussion, if chemicals or nanomaterials are released, they will be toxic. That is only the beginning. We need to discuss how much is released. There’s a principal in toxicology that everything is toxic. If you drink too much water, it can be toxic and you can die. Similar [rules] apply for nanomaterials. If there is a little released, the danger might be minimal. If it’s too much, that’s where you might get concerned. [The amount of a nanomaterial released] is often not quantified. That’s what we are trying to do.

TBR: How do you determine what might be toxic over a prolonged period of time?

Orlov: What we have in our studies are determined by funding. Normally, funding for scientific research has a three-year window. The studies have been done over the course of years, but not decades, and so the cumulative exposure is still an open question. Another problem is that different scientific groups study nanomaterials which are not the same. That means there are so many variants. Sometimes, navigating the literature is almost impossible.

TBR: Are the studies on toxicity keeping up with the development of new products?

Orlov: [The technology is] developing so fast. New materials are coming from different labs and have so many potential applications, which are exciting and novel in their properties. People studying safety and toxicity often can’t catch up with what they are studying in their lab.

TBR: Are there efforts to recapture nanomaterials released into the environment?

Orlov: Once released, it’s difficult to recapture. [It’s almost] like air pollution, where as soon as it’s in the atmosphere, it can go anywhere. There are industries that use nanomaterials. Soon, you’ll see 3-D printers in the household; 3-D printers would use polymers and embedded nanomaterials. There are already products like this. The question is how you would minimize consumer exposure. There are several ways: design safer products where nanomaterials aren’t going to be released; apply the standard methods of occupational safety; put equipment in ventilated environment; and you can also try to calculate the exposure.

TBR: Are you monitoring nanomaterials in some of these applications?

Orlov: The research we’ve done demonstrated that, even though you have something in polymer or in consumer products, [there is] still [the] possibility of release of nanomaterials, even though it is considered safe. The polymer itself can degrade.

TBR: Do you have any nanoparticle nightmares?

Orlov: Often, the only nightmares I have is that my understanding of the field is so minuscule given that the field is expanding so fast. The amount of knowledge generated and papers published in this is so vast that no single individual can have a comprehensive knowledge in this field. The only way to address it is to collaborate.

TBR: How is the funding environment?

Orlov: In the United States, there’s a significant amount of funding in both fundamental and applied research, but the policy priorities change in certain areas such as environmental protection, so that affects scientists who are working in the environmental area. I teach environmental classes at Stony Brook. Students ask whether it makes sense to go into environmental protection because of the current funding and general policies.

TBR: What do you advise them to do?

Orlov: I tell them priorities change. At the end of the day, would they like to have clean water and a healthy environment and healthy humans? You can find a niche. It doesn’t make sense to abandon this area.

TBR: You experienced the fallout from Chernobyl firsthand. How often do you think about this?

Orlov: I do think about this often for several reasons. There is an overlap in energy and the environment. This idea that scientific discoveries have positive and negative impacts on humanity came during that time. When I was in the Ukraine and disaster happened, I think about this a lot of times.

TBR: How does a career in science compare to your expectations?

Orlov: My original thinking is that after you get to a certain level, you have a more measured life, in terms of free time and time spent in research. I didn’t realize that the amount of funding or probability of getting funding is becoming very low. When I looked at my colleagues who were scientists 30 years ago, they had a five times higher chance of getting funding compared to right now. Being in science is not as relaxing and it can be stressful and the thing is, if you only focus on getting funding, the creativity can suffer.

TBR: Are there other examples of the dichotomy between scientific promise and destruction?

Orlov: In my introductory lecture to chemical engineers at Stony Brook, one scientist who affected more people than Stalin or Hitler was a German scientist who developed the process of converting nitrogen [gas] to ammonia [which is used for fertilizer]. Half of the population exists because of this scientific discovery. [One of the inventors, Fritz Haber, received the Nobel Prize in Chemistry in 1918 for this work, called the Haber-Bosch process].

TBR: What else did he do?

Orlov: Haber had a dark side to him. He was involved in developing chemical weapons for Germans [which were used during World War I and World War II]. The [extension of his] discoveries killed millions of people [including Haber’s relatives in World War II after he died]. Considered the father of chemical warfare, he developed the process of weaponizing chlorine gas. This is [a way] to discuss the ethics of scientific discovery.

TBR: How would people learn about these examples?

Orlov: Stony Brook and other universities are trying to teach ethics to engineers and scientists because this is a perfect example of the dark side of science and how science and policy overlap.

by -
0 341
Heather Lynch visits Cape Lookout in Antarctica during recent trip that included an NBC TV crew that produced a feature for ‘Sunday Night with Megan Kelly.’ Photo by Jeff Topham

By Daniel Dunaief

Heather Lynch is thrilled that she’s in the first class of scientists chosen as a recipient of the National Geographic AI for Earth Innovation Grant.

An associate professor of ecology and evolution at Stony Brook University, Lynch uses computers to study satellite images to reveal details about populations of penguins.

In addition to determining how many penguins are in an area, Lynch also can use images of the stains penguin poop leaves on rocks to determine what the penguins eat. Krill, which feeds on the underside of ice, is reddish or pinkish, while fish leave a white stain.

Heather Lynch with a penguin. Photo from Heather Lynch

A total of 11 researchers won the grants, which are a combined award from Microsoft and the National Geographic Society and were announced in December. The winners were chosen from more than 200 qualified scientists.

“This is the first grant that National Geographic and Microsoft are doing,” Lynch said. “It’s super exciting to be in the inaugural group.”

To hear from Lynch’s colleagues, she is an extraordinary candidate for a host of awards, including recognition as one of the TBR News Media People of the Year for 2018.

In addition to landing a coveted grant for her innovative research using sophisticated computers and satellite images, Lynch earlier this year made a remarkable discovery using Landsat imagery about a population of Adélie penguins on the Danger Islands in the Antarctic that was largely unknown prior to her published paper.

This archipelago of nine islands, which were named because of the ice that is impenetrable in most years, was home to 1.5 million penguins, which she surveyed using a combination of photos, drone imagery and hand counting. That figure represents a substantial population of a charismatic animal whose numbers often are used as a way to determine the health of a delicate region managed by a collection of nations.

“She does such good work,” said Patricia Wright, a distinguished service professor at Stony Brook University and the founder and executive director of Centre ValBio, a research station in Madagascar. Her discovery of the additional Adélie penguins was “fantastic.”

Lynch received some pushback from people who thought the discovery of these penguins ran counter to the narrative about the need for conservation. Wright appreciates how Lynch shared the discovery with the public, reinforcing her scientific credibility.

“She’s an example of a scientist who doesn’t give in to political pressure,” Wright said. “It’s difficult sometimes to face up to people who have good intentions, but who don’t seem to want to accept the reality.”

While the discovery of the Adélie penguins was remarkable, it doesn’t necessarily run contrary to the notion about the delicate balance of the Antarctic ecosystem, and it also doesn’t indicate that the population is soaring in a way the flightless water fowl never will. Indeed, the 1.5 million penguins may have been higher in the 1990s, although she is working to pin down exactly how much larger they might have once been.

Heather Lynch at Spigot Peak in the Antarctic. Photo by Catherine Foley

Lynch has also won admiration and appreciation from Assemblyman Steve Englebright (D-Setauket), who recently won his 14th term and has focused attention on environmental issues.

“Her ability to use statistics and mathematics to further conservation biology is pioneering work and worthy of recognition,” Englebright said.

The assemblyman believes scientists and policymakers are still in the early part of the process of understanding the complexity of the ecosystems in the Antarctic.

Finding the penguins on the Danger Islands doesn’t mean the “Antarctic is any less at risk. We still have to place that discovery into its proper context and [Lynch] is helping us do that,” Englebright said.

People who have ventured to the Antarctic with her admire Lynch’s focus, energy
and stamina.

Michelle LaRue, who is a lecturer at the University of Canterbury in New Zealand, suggested that Lynch was “the most hardworking scientist that I know.”

LaRue recalled a time when Lynch was ill, and she still got up and did her job every day.

“The work we were doing wasn’t easy,” LaRue said. “I know she didn’t feel well and she kept going. She has a lot of perseverance.”

LaRue appreciates how her fellow scientist sees the “forest for the trees,” using a combination of high technology and considerable on-site counting to understand what changes in the penguin population reveal about the region.

Michael Polito, an assistant professor in the Department of Oceanography and Coastal Sciences at Louisiana State University, has also worked with Lynch for years. He appreciates how she’s “not afraid of uncertainty. In science, it’s knowing how well you know something. She’s amazing at taking data and information, which from the natural world is messy, and analyzing it and helping people pull useful and meaningful knowledge from complex situations.”

Ron Naveen, who founded the nonprofit group Oceanites in 1987, has worked with Lynch for 11 years.

“I’m very much proud of her work ethic and the standard of excellence she brings to the job,” Naveen said.

Oceanites collaborates with Lynch and others, Naveen said, to understand how penguins have reacted to climate change in an area where temperatures have been increasing at a faster rate than they have for much of the rest of the world.

Naveen recalls how Lynch, whom he describes as “petite and energetic” lugged around “amazingly heavy equipment,” including a camera for a Google Earth project.

“Whether [Lynch] is hiking, using a satellite or a drone, or lugging equipment that’s heavier than she is, she gets the data,” Naveen said.

He recalled a lab meeting with Lynch, who was a postdoctoral researcher at the University of Maryland in the lab of William Fagan. Lynch circled the room as she wrote on the board, sharing statistical language to explain a point.

“I had no bloody idea what she was talking about,” Naveen said. “When she was done, she sat down with a smile, and I raised my hand and innocently asked, ‘Would you mind translating that into plain English?’ Without missing a beat, she did.”

By all accounts, she’s continuing to do that.

by -
0 2061
Francis Alexander. Photo from BNL

By Daniel Dunaief

Now what? It’s a question that affects everyone from the quarterback who wins the Super Bowl — who often says something about visiting a Disney facility — to the student who earns a college degree, to the researcher who has published a paper sharing results with the scientific community.

For some, the path forward is akin to following footsteps in the snow, moving ever closer to a destination for which a path is clear. For others, particularly those developing new technology, looking to unlock mysteries, the path is more like trudging through unfamiliar terrain.

The technology at facilities like Brookhaven National Laboratory, which includes the powerful National Synchrotron Light Source II and the Center for Functional Nanomaterials, among others, enables scientists to see processes at incredibly fine scales.

While these sites offer the promise of providing a greater ability to address questions such as what causes some batteries to die sooner than others, they also cost considerable money to use, putting pressure on researchers to ask the most fruitful question or pursue research that has the greatest chance for success.

Francis Alexander. Photo from BNL

That’s where people like Francis Alexander, the deputy director of Brookhaven National Laboratory’s Computational Science Initiative, and his team at BNL can add considerable value. Alexander takes what researchers have discovered, couples it with other knowledge, and helps guide his fellow laboratory scientists to the next steps in their work — even if he, himself, isn’t conducting these experiments.

“Given our theoretical understanding of what’s going on, as imperfect as that may be, we take that understanding — the theory plus the experimental data — and determine what experiments we should do next,” Alexander said. “That will get us to our goal more quickly with limited resources.”

This approach offers a mutually reinforcing feedback loop between discoveries and interpretations of those discoveries, helping researchers appreciate what their results might show, while directing them toward the next best experiment.

The experiments, in turn, can either reinforce the theory or can challenge previous ideas or results, forcing theoreticians like Alexander to use that data to reconstruct models that take a wide range of information into account.

Alexander is hoping to begin a project in which he works on developing products with specific properties. He plans to apply his knowledge of theoretical physics to polymers that will separate or grow into different structures. “We want to grow a structure with a [particular] function” that has specific properties, he said.

This work is in the early stages in which the first goal is to find the linkage between what is known about some materials and what scientists can extrapolate based on the available experiments and data.

Alexander said the aerospace industry has “models of everything they do.” They run “complex computer simulations [because] they want to know how they’d design something and which design to carry out.”

Alexander is currently the head of a co-design center, ExaLearn, that focuses on exascale, machine-learning technologies. The center is the sixth through the Exascale Computing Project. Growth in the amount of data and computational power is rapidly changing the world of machine learning and artificial intelligence. The applications for this type of technology range from computational and experimental science to engineering and the complex systems that support them.

Ultimately, the exascale project hopes to create a scalable and sustainable software framework for machine learning that links applied math and computer science communities to create designs for learning.

Alexander “brings to machine learning a strong background in science that is often lacking in the field,” Edward Dougherty, a distinguished professor in the Department of Electrical and Computer Engineering at Texas A&M, wrote in an email. He is an “excellent choice to lead the exascale machine learning effort at Brookhaven.”

Alexander is eager to lead an attempt he suggested would advance scientific and national security work at the Department of Energy. “There are eight national laboratories involved and all the labs are on an equal level,” he said. 

One of the goals of the exascale computing project is to build machines capable of 10 to the 18th operations per second. “There’s this enormous investment of DOE” in this project, Alexander said.

Once the project is completely operational, Alexander expects that this work will take about 30 percent of his time. About 20 percent of the time, he’ll spend on other projects, which leaves him with about half of his workweek dedicated to management.

The deputy director recognizes that he will be coordinating an effort that involves numerous scientists accustomed to setting their own agenda.

Dougherty suggested that Alexander’s connections would help ensure his success, adding that he has “established a strong network of contacts in important application areas such as health care and materials.

The national laboratories are akin to players in a professional sporting league. They compete against each other regularly, bidding for projects and working to be the first to make a new discovery. Extending the sports metaphor, members of these labs often collaborate on broad projects, like players on an all-star team competing against similar teams from other nations or continents.

Alexander grew up in Ohio and wound up working at Los Alamos National Laboratory in New Mexico  for over 20 years. He came to BNL in 2017 because he felt he “had the opportunity to build something almost from the ground up.” The program he had been leading at Los Alamos was large and well developed, even as it was still growing. 

The experimental scientists at BNL have been receptive to working with Alexander, which has helped him achieve some of his early goals.

Ultimately, Alexander hopes his work increases the efficiency of numerous basic and applied science efforts. He hopes to help experimental scientists understand “what technologies we should develop that will be feasible” and “what technologies would be most useful to carry experiments out.”

by -
0 2404
Aaron Sasson. Photo courtesy of Stony Brook Medicine

By Daniel Dunaief

Thanks to the efforts of Stony Brook University School of Medicine’s Chief of Surgical Oncology Aaron Sasson and numerous doctors and researchers at Stony Brook, Long Island has its first National Pancreas Foundation Center.

A nonprofit organization, the National Pancreas Foundation goes through an extensive screening process to designate such centers around the country, recognizing those that focus on multidisciplinary treatment of pancreatic cancer. The NPF offers this distinction to those institutions that treat the whole patient and that offer some of the best outcomes and improved quality of life for people suffering with a disease who have an 8 percent survival rate five years after diagnosis.

Sasson appreciates the team effort at the medical school. “As opposed to one person leading this, there are many people here who are required to have an interest in pancreatic cancer,” he said. “We are not only looking to build a great infrastructure for the treatment of pancreatic cancer, but we’re also looking to build a team for research on pancreatic cancer.”

Sasson highlighted the research efforts led by Yusuf Hannun, the director of the Cancer Center at SBU, who has helped attract a “tremendous number of scientists” to engage in research into this disease.

The recognition by the NPF helps the university recruit physicians who are clinically interested in developing ways to improve the outcome for patients.

Pancreatic cancer presents particular challenges complicated by its biological aggressiveness, its difficulty to detect and by the many subtypes of this disease. “It’s similar to lung and breast cancer,” Sasson said. “There are many facets of those cancers. You can’t lump them all together.”

Researchers and clinicians are still trying to understand pancreatic cancer in greater detail. Once they have done that, they can advance to treating the possible subtypes.

Numerous researchers at SBU have developed collaborations with scientists at Cold Spring Harbor Laboratory. David Tuveson, the director of the National Cancer Institute-designated Cancer Center, has engaged in collaborations with SBU scientists in his work on organoids, which are model human organs grown in a lab. Scientists use organoids to test drugs and molecular pathways involved in pancreatic cancer.

Members of the Long Island community can take comfort in the continuing dedication of the numerous staff members committed to finding a cure. “Residents of Suffolk County and Long Island should be proud of what Stony Brook has been able to accomplish,” Sasson said.

Stony Brook University has been involved in several clinical efforts. The university developed a drug called CPI-613, for which Rafael Pharmaceuticals is in the early stage of clinical trials in combination with other drugs.

In early stages, the treatment increases the vulnerability of cancer cells to numerous other drugs. Newark, New Jersey-based Rafael Pharmaceuticals is testing this treatment in pancreatic cancer and in acute myeloid leukemia.

At SBU facilities, Sasson explained that researchers and clinicians are taking a multidisciplinary approach in their work. One study, he said, is exploring the effects of a kind of radiation therapy for a subpopulation of pancreatic cancer that combines expertise in radiology, gastroenterology, pathology and medical and surgical oncology.

Sasson himself is interested in screening and biomarkers. At least half of his work is related to pancreatic cancer. When he thinks about people who have battled pancreatic cancer, several patients come to mind. He had a patient who was about 80 at the time of his diagnosis. His primary doctor told him to get his affairs in order.

“We operated on him and he lived another six or seven years,” Sasson recalls. “He was grateful to see his grandchildren graduate and to see his great-grandbabies being born.”

While every patient is unlikely to have the same outcome, Sasson said surrendering to the disease and preparing for the inevitable may not be the only option, as there may be other courses of action.

Another patient had advanced pancreatic cancer for 18 months before Sasson met her. She had received no treatment and yet the cancer didn’t progress, which is “almost unheard of and unbelievable.” In fact, the case defied medical expectations so dramatically that the doctors conducted two more biopsies to confirm that she had pancreatic cancer. “She did well for many years despite having advanced pancreatic cancer.”

In another case, a patient was receiving surveillance for lung cancer every three months. In between those visits, he had developed metastatic pancreatic cancer. This patient example and the previous one show the range of cancer progression.

The value of having an integrated clinical and research program is that scientists can look for subtle clues and signals amid the reality of cancer with a wide range of outcomes. Indeed, scientists attend the weekly tumor board meeting, so they can learn about the clinical aspects of the disease. Doctors also attend research collaborations so they can hear about developments in the lab.

Rather than dictating how researchers and clinicians should collaborate, Sasson hopes to facilitate an environment that sparks these partnerships.

Sasson joined Stony Brook Medical School almost three years ago. He said he is “impressed with the caliber of physicians.” It took time to get the critical mass and organization for pancreatic cancer to match the number of basic science investigators.

“I’m hopeful for the progress we’ll be able to make to treat this terrible disease,” he said.

Prev1...456...10Next Page 5 of 10
TBR News Media is your local news and entertainment website.
We provide you with the latest breaking news and information for your community.
Contact us: [email protected]

Most Viewed

©